Our Science & DRP™ technology

Not all cancer patients will benefit from treatment with cancer drugs


– and in addition, patients may experience negative side effects from the treatment. Until now, it has been very hard to predict in which indication a cancer drug candidate will be effective and who will benefit from the treatment. There is a general acceptance of this in the market and there are examples of very expensive cancer products with effect in only a fraction of the treated patients. The development of cancer drugs and the treatment of cancer is rapidly changing from population-based experience towards more precise individualized treatment (Precision Medicine). Cancer classification and its treatment was until recently exclusively based on population-based observations, but due to great inter-individual variation, the old methods came with low sensitivity and low specificity.

The DRP™ pioneering approach utilizes a proprietary method to analyze the genomic fingerprint in each individual tumor, which allows us to predict whether a patient is likely to benefit from a certain drug or not. The DRP™ tool is cutting edge and can be used together with existing methods to increase the ability to identify both responders and non-responders to a given cancer drug. Following the sequencing of the Human Genome, quantitative methods have advanced and our understanding of complex biological signals have improved substantially. This science has enabled a search for new and more efficacious genomic biomarkers, which reflect certain biological or disease-generating processes in the cancer cell. With the DRP™ approach, we share the anticipation that these methods, which provide increased understanding of the complexity of the molecular mechanisms underlying the development of cancer, will allow us to identify both responders and non-responders to a given cancer drug therapy. Consequently, the value proposition of the DRP™ technology delivers the following win-win-win situation:

  • Win for the individual patient who receives guidance on which drugs are likely to kill the cancer and/or which drugs are unlikely to eliminate the cancer. If the patient starts early therapy with an efficacious drug, this may have strong impact on outcome.

  • Win for payors the Drug Response Prediction, DRP-technology, can identify non-responders and will reduce costs associated with in-efficacious first-line therapy and subsequent rescue medication and bring more value for money.

  • Win for drug development companies. A study has shown that only 4.7% of cancer drugs in clinical development are expected to lead to a marketing approval.

The costs for clinical studies are very high. It is estimated that the cost for investigating a cancer drug per patient in clinical phase 1-, 2- and 3 trials is USD 45-65,000. It is seldom a cancer drug is approved with data from less than 1,000 patients. The development costs for cancer drugs marketed in USA and Europe has on average been over USD 1 billion. The interest from cancer drug developers is therefore expected to be significant as the DRP-technology can reduce development costs significantly. OV is utilizing the in-licensed DRP™ technology from MPI to constantly building evidence to create value to the oncology community to help identify the right patients for the right cancer drug.

Clinical trial design

Oncology Venture has a license from Medical Prognosis Institute A/S (Short name: MPI.ST) to use the technology Drug Response Prediction (DRP™). MPI is listed on NASDAQ First North in Stockholm. Via DRP™, identification of which patients might respond to a drug candidate can be made, increasing the probability that the candidate will be successful in clinical trials.

OV’s business idea is to pick up anticancer drugs stopped in clinical development – which has shown sporadic effect but nut sufficient to achieve marketing approval. Oncology Venture works with a DRP™ technology  which changes the odds in comparison with traditional drug development. Instead of treating all patients with a particular type of cancer, patients are screened first, and only those most likely to respond to the treatment will be included in focused phase 2 trials to demonstrate Proof of concept. Via a better-defined patient group, risks and costs are reduced while at the same time the development process becomes more efficient.